Emergent BioSolutions wins $56M ACAM2000 contract

Emergent BioSolutions entered into a new, material agreement with the U.S. government tied to its smallpox vaccine.

Rhea-AI Filing Summary

Emergent BioSolutions entered into a new, material agreement with the U.S. government tied to its smallpox vaccine. On September 5, 2025, a contract modification from the Office of the Assistant Secretary for Preparedness and Response exercised Option Year 6 under the existing 10-year ACAM2000® contract. The modification is valued at $56 million and requires Emergent to deliver doses of its ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) to the U.S. government by December 31, 2025.

The company also referenced that the full text of this modification will be filed with its next quarterly report, and that the base ACAM2000 contract is already on file as a material agreement. In a related move, Emergent issued a press release on September 9, 2025 describing the modification, which is attached as an exhibit to this report for investors seeking additional detail.

Insights

Biopharma government-contracts analyst

$56M option year extends U.S. smallpox vaccine supply relationship.

Emergent BioSolutions received a $56 million contract modification exercising Option Year 6 under its 10-year ACAM2000® smallpox vaccine agreement with ASPR. This confirms continued U.S. government demand for ACAM2000 and locks in funded deliveries of vaccine doses through December 31, 2025.

The agreement is described as a material definitive contract, underscoring its importance to Emergent’s government-facing portfolio. Revenue recognition will depend on the timing of dose deliveries and any related performance obligations defined in the modification and underlying ACAM2000 contract.

Investors may focus on how this $56 million of contracted value contributes to Emergent’s overall product sales mix and cash generation for the period up to December 31, 2025. Further detail is expected when the company files the full text of Modification No. 14 with its next Form 10‑Q.

8-K Event Classification

3 items: 1.01, 7.01, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What contract did Emergent BioSolutions (EBS) announce in this 8-K?

Emergent BioSolutions announced that its wholly owned subsidiary received Modification No. 14 from ASPR, exercising Option Year 6 under the existing 10-year ACAM2000® contract with the U.S. government.

How much is the new ACAM2000 contract modification worth for EBS?

The ACAM2000 contract modification, identified as Modification No. 14, is valued at $56 million for Emergent BioSolutions.

What product is Emergent BioSolutions supplying under this $56 million option year?

Under this option year, Emergent BioSolutions will supply ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) to the U.S. government.

By when must Emergent BioSolutions deliver ACAM2000 doses under Modification No. 14?

Emergent BioSolutions is required to deliver the ACAM2000 vaccine doses to the U.S. government by December 31, 2025 under Modification No. 14.

Where can investors find the full text of the new ACAM2000 contract modification?

The company expects to file the full text of Modification No. 14 as an exhibit to its next Quarterly Report on Form 10-Q. The underlying ACAM2000 contract is already filed as exhibit 10.48 to the Form 10-K for the year ended December 31, 2019.

Did Emergent BioSolutions issue a press release about this ACAM2000 contract update?

Yes. Emergent BioSolutions issued a press release on September 9, 2025 announcing Modification No. 14. The press release is furnished as Exhibit 99.1 to this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/11/2025 - 04:07 PM Learn about SEC filing dates

0001367644false00013676442025-09-052025-09-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 5, 2025

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33137

14-1902018

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

 300 Professional Drive,

Gaithersburg, Maryland 20879

(Address of principal executive offices, including zip code)

(240) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			EBS			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01    Entry into a Material Definitive Agreement

On September 5, 2025, Emergent BioSolutions Inc. (the “Company,” including its wholly-owned subsidiaries, “Emergent”), through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response (“ASPR”), an agency of the U.S. Department of Health and Human Services (“Modification No. 14”), exercising Option Year 6 for Emergent to supply ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) to the U.S. government under Emergent’s existing 10-year contract with ASPR (the “ACAM2000 Contract”). Modification No. 14 is valued at $56 million and requires Emergent to deliver doses of ACAM2000 to the U.S. government by December 31, 2025.

The preceding description of Modification 14 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification 14. A copy of Modification 14 is expected to be filed as an exhibit to the Company’s next Quarterly Report on Form 10-Q. The ACAM2000 Contract is filed as a material agreement of Emergent as exhibit 10.48 with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019.

Item 7.01    Regulation FD Disclosure.

On September 9, 2025, the Company issued a press release announcing Modification No. 14. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press release issued by Emergent BioSolutions Inc. on September 9, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			EMERGENT BIOSOLUTIONS INC.
Dated: September 11, 2025			By:			/s/ RICHARD S. LINDAHL
						Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial              Officer and Treasurer